Actuate Therapeutics, Inc. (NASDAQ: ACTU) has priced an underwritten public offering of 2,142,858 shares of its common stock at $7.00 per share, with an option for underwriters to purchase additional shares. The offering is expected to close on September 11, 2025, raising approximately $15.0 million in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes. Actuate Therapeutics is focused on developing therapies for difficult-to-treat cancers, with their lead drug targeting molecular pathways involved in tumor growth and resistance to conventional treatments.

Read more at GlobeNewswire: Actuate Therapeutics Announces Pricing of $15.0 Million